The FTSE 100 has gone on a tear just as the deadline for using this year’s Stocks and Shares ISA allowance looms. So is there still good value out there? Happily, I think there is. As with any rally, some shares refused to participate. That applies to one of my favourite portfolio holdings, wealth manager ...
motleyfooluklse:gsklse:rtolse:mng
With a forward-looking yield near 4%, FTSE 100 dividend stock GSK (LSE: GSK) looks tempting for shareholder income. But the biopharmaceutical company has its sights firmly set on rebooting its growth mojo. And there’s mounting evidence the business may be succeeding in that ambition. So my assumption ...
motleyfooluklse:gsk
I’m looking to top up my Stocks and Shares ISA before April’s deadline, and the following FTSE 100 stocks have all caught my eye. They’re the type of companies investors overlook, so there’s not much froth in their valuations. I’m a longstanding fan of unsung hero Bunzl (LSE: BNZL). This £11bn outsourcing ...
motleyfooluklse:gsklse:bnzllse:sdr
GSK’s (LSE: GSK) share price is around an 18-month high. But just because a stock has risen a lot does not automatically mean that it is overvalued. It could simply be that the company is worth more than it was before. In fact, it could well be worth even more than the current share price reflects. Undervalued ...
motleyfooluklse:gsk
Premium content from Motley Fool Share Advisor UK Our monthly Ice Best Buys Now are designed to highlight our teamâs three favourite, most timely Buys from our growing list of income-focused Ice recommendations, to help Fools build out their portfolios. âBest Buys Nowâ Pick #1: GSK (LSE: GSK) In ...
motleyfooluklse:gsk
Financial services and pharmaceuticals are two very different industries. I think one stock from each of these could prove to be excellent income stocks. The two picks I’m referring to are abrdn (LSE: ABDN) and GSK (LSE: GSK). Here’s why I reckon investors should consider buying some shares. abrdn Since ...
motleyfooluklse:gsklse:abdn